(Q36562239)

14 August 2017

1 reference

title

Fibrate therapy in patients with metabolic syndrome and diabetes mellitus (English)

1 reference

14 August 2017

1 reference

1

Thomas Dayspring

1 reference

14 August 2017

Gregory Pokrywka

2

1 reference

14 August 2017

1 September 2006

1 reference

Current Atherosclerosis Reports

14 August 2017

1 reference

14 August 2017

8

1 reference

14 August 2017

5

1 reference

14 August 2017

356-364

1 reference

https://scigraph.springernature.com/pub.10.1007/s11883-006-0032-x

14 August 2017

0 references

cites work

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0032-X

Effect of a combination of gemfibrozil and niacin on lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0032-X

A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0032-X

Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-006-0032-X

Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS11883-006-0032-X

21 January 2018

12 December 2020

Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients

1 reference

12 December 2020

Mechanistic studies on metabolic interactions between gemfibrozil and statins

1 reference

12 December 2020

High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study

1 reference

12 December 2020

Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study

1 reference

12 December 2020

Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease

1 reference

12 December 2020

Cell culture conditions determine apolipoprotein CIII secretion and regulation by fibrates in human hepatoma HepG2 cells

1 reference

12 December 2020

The changing face of cardiovascular risk.

1 reference

12 December 2020

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

12 December 2020

Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease

1 reference

12 December 2020

Pharmacokinetic interactions between statins and fibrates

1 reference

12 December 2020

PPAR- and LXR-dependent pathways controlling lipid metabolism and the development of atherosclerosis

1 reference

12 December 2020

Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome

1 reference

12 December 2020

Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control

1 reference

12 December 2020

Pleiotropic effects of fibrates

1 reference

12 December 2020

Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study

1 reference

12 December 2020

Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT).

1 reference

12 December 2020

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

12 December 2020

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha controls cellular cholesterol trafficking in macrophages

1 reference

12 December 2020

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

12 December 2020

Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients

1 reference

12 December 2020

Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT).

1 reference

12 December 2020

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

1 reference

12 December 2020

Dual roles of apolipoprotein CI in the formation of atherogenic remnants

1 reference

12 December 2020

Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

1 reference

12 December 2020

Serum homocysteine concentrations, gemfibrozil treatment, and progression of coronary atherosclerosis.

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

Effect of gemfibrozil on apolipoprotein B secretion and diacylglycerol acyltransferase activity in human hepatoblastoma (HepG2) cells

1 reference

12 December 2020

Lipoprotein remnants and endothelial dysfunction in the postprandial phase

1 reference

12 December 2020

Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio

1 reference

12 December 2020

Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients

1 reference

12 December 2020

Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

1 reference

12 December 2020

Discrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptor

1 reference

12 December 2020

Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

1 reference

12 December 2020

Fenofibrate reduces plasma cholesteryl ester transfer from HDL to VLDL and normalizes the atherogenic, dense LDL profile in combined hyperlipidemia

1 reference

12 December 2020

Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin

1 reference

12 December 2020

Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner

1 reference

12 December 2020

Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial

1 reference

12 December 2020

Effects of various fibrates on serum alkaline phosphatase activity.

1 reference

12 December 2020

PPARα controls the intracellular coenzyme A concentration via regulation of PANK1α gene expression

1 reference

12 December 2020

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

1 reference

12 December 2020

Role of fibric acid derivatives in the management of risk factors for coronary heart disease

1 reference

12 December 2020

Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia

1 reference

12 December 2020

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

1 reference

12 December 2020

Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate

1 reference

12 December 2020

Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

1 reference

12 December 2020

PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway

1 reference

12 December 2020

Relation between on-treatment increments in serum high-density lipoprotein cholesterol levels and cardiac mortality in patients with coronary heart disease (from the Bezafibrate Infarction Prevention trial).

1 reference

12 December 2020

Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

1 reference

12 December 2020

Peroxisome proliferator-activated receptor alpha is required for feedback regulation of highly unsaturated fatty acid synthesis

1 reference

12 December 2020

Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia

1 reference

12 December 2020

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

12 December 2020

Fenofibrate increases creatininemia by increasing metabolic production of creatinine

1 reference

12 December 2020

Peroxisome proliferator-activated receptors: how their effects on macrophages can lead to the development of a new drug therapy against atherosclerosis

1 reference

12 December 2020

Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment

1 reference

12 December 2020

Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance

1 reference

12 December 2020

Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus

1 reference

12 December 2020

Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

1 reference

12 December 2020

The mechanisms of action of PPARs

1 reference

12 December 2020

The triglyceride-high-density lipoprotein axis: an important target of therapy?

1 reference

12 December 2020

Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia

1 reference

12 December 2020

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

1 reference

12 December 2020

10.1007/S11883-006-0032-X

Identifiers

DOI

1 reference

14 August 2017

1 reference

PubMed ID

16901405